Engineered bacteria as therapeutic agents. (December 2015)

• Record Type: Journal Article
• Authors: Piñero-Lambea, Carlos; Ruano-Gallego, David; Fernández, Luis Ángel
• Is Part Of: Current opinion in biotechnology. Volume 35(2015)
• Page Start: 94
• Page End: 102
• Publication Date: 2015-12
• Subjects: Biotechnology -- Periodicals; 660.6
• DOI: 10.1016/j.copbio.2015.05.004
• Languages: English
• ISSNs: 0958-1669

Abstract

Graphical abstract: Highlights: Engineered bacteria provide a continuous supply of therapeutic molecules. Bacterial therapies target inflammation, immunity, cancer, and metabolic disorders. Novel strategies deliver transcription factors and enzymes to reprogram host cells. Synthetic biology allows the design of safe bacteria for therapy. Abstract : Although bacteria are generally regarded as the causative agents of infectious diseases, most bacteria inhabiting the human body are non-pathogenic and some of them can be turned, after proper engineering, into 'smart' living therapeutics of defined properties for the treatment of different illnesses. This review focuses on recent developments to engineer bacteria for the treatment of diverse human pathologies, including inflammatory bowel diseases, autoimmune disorders, cancer, metabolic diseases and obesity, as well as to combat bacterial and viral infections. We discuss significant advances provided by synthetic biology to fully reprogram bacteria as human therapeutics, including novel measures for strict biocontainment.